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Abstract
Background: A natural bispecific antibody, which can be produced by exchanging Fab arms of two IgG4 molecules, was
first described in allergic patients receiving therapeutic injections with two distinct allergens. However, no information has
been published on the production of natural bispecific antibody in animals. Even more important, establishment of an
animal model is a useful approach to investigate and characterize the naturally occurring antibody.
Methodology/Principal Findings: We demonstrated that a natural bispecific antibody can also be generated in New
Zealand white rabbits by immunization with synthesized conjugates. These antibodies showed bispecificity to the
components that were simultaneously used to immunize the animals. We observed a trend in our test animals that female
rabbits exhibited stronger bispecific antibody responses than males. The bispecific antibody was monomeric and primarily
belonged to immunoglobulin (Ig) G. Moreover, bispecific antibodies were demonstrated by mixing 2 purified monospecific
antibodies in vivo and in vitro.
Conclusions/Significance: Our results extend the context of natural bispecific antibodies on the basis of bispecific IgG4, and
may provide insights into the exploration of native bispecific antibodies in immunological diseases.
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Introduction
Antibodies exist as one or more copies of a Y-shaped unit. Each
Y-shaped unit contains 4 polypeptides, 2 identical copies of a
polypeptide known as the heavy chain and 2 identical copies of a
polypeptide called the light chain. Immunoglobulin G (IgG)
antibodies contain only 1 structural Y-shaped unit and are also the
most abundant in serum. The enzyme papain cleaves an IgG
molecule into 3 active fragments. Two of these are identical
antigen-binding fragments (Fab), which form the arms of the Y
and make an IgG molecule bivalent. The third fragment, which
forms the base of the Y, is called Fc fragment because it is readily
crystallized. This region is important in mediating the effector
functions of the antibody in immune responses [1].
Bispecific antibody, as its name indicates, usually consists of 2
distinct Fab arms, by which it is capable of simultaneously binding
two different antigens. This characteristic confers bispecific
antibody immense potential for a wide range of clinical
applications as targeting agents for immunodiagnosis and therapy.
It is believed that bispecific antibody usually do not occur naturally
but are constructed artificially by recombinant DNA or cell-fusion
technologies [2]. However, a class of natural bispecific antibody
was recently obtained from allergic patients receiving therapeutic
injections with 2 different allergens during specific immunotherapy
[3]. It was indicated that the antibody with bispecificity belonged
to the IgG4 subclass. IgG4 antibodies are dynamic molecules that
exchange their Fab arms by swapping a heavy chain and attached
light chain (half-molecule) with a heavy-light chain pair from
another molecule, resulting in bispecific antibodies [3–4]. This has
been demonstrated in a rhesus monkey model with experimental
autoimmune myasthenia gravis. Interestingly, the exchanged IgG4
did not cause disease, instead, it appeared to protect the animal
from IgG1-mediated inflammation, probably by displacing the
IgG1 and binding monovalently to acetylcholine receptors (AchR)
[4]. Nevertheless, the origin of natural bispecific antibodies and
their significances remain to be further determined.
In this report, we described our investigations on animal models
for the production of natural bispecific antibodies against different
synthesized conjugates. Purified bispecific antibodies were ob-
tained and their characteristics were examined.
Materials and Methods
Conjugation
Digoxin, horseradish peroxidase (HRP), keyhole limpet hemo-
cyanin (KLH), and bovine serum albumin (BSA) were purchased
from Sigma-Aldrich (St. Louis, MO, USA). KLH-dinitrophenyl
(KLH-DNP) conjugates were obtained from Merck (Darmstadt,
Germany). BSA-DNP was purchased from Biosearch Technolo-
gies (Novato, CA).
Digoxin was conjugated to BSA using a previously described
method [5–6]. The efficiency of conjugation was evaluated
spectrophotometrically in 83% H2SO4 [7]. To establish enzyme-
linked immunosorbent assays (ELISA), each of the 4 antigens,
BSA, KLH, DNP, and digoxin, was labeled with HRP, using the
periodate oxidation method [5]. After purification, the optimal
working concentration for each enzyme conjugate was determined
by chessboard titrations [8].
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24 New Zealand white rabbits were allocated to 6 groups
marked as (1) BSA group, (2) Digoxin group, (3) BSA-digoxin
group, (4) BSA-DNP group, (5) KLH-DNP group, and (6) BSA-
Digoxin/KLH-DNP mixed group. Each group comprised 2 males
and 2 female rabbits. Blank sera were obtained before the
immunization procedure. For primary immunization, immuno-
gens were dissolved in 0.85% saline at a concentration of 2 mg/
mL and emulsified with an equal volume of complete Freund’s
adjuvant (CFA), which contained approximately 1 mg/mL of
killed tubercle bacilli [9]. The rabbits were immunized subcuta-
neously at multiple sites along the spinal cord. After 3 months,
booster injections were administered with incomplete Freund’s
adjuvant (IFA), at a dose equivalent to half of the primary. The
procedure was performed at 2-month intervals for 7 months [10].
Blood was drawn from the marginal ear vein and the titers of
antibodies were evaluated.
All rabbits were raised under standardized pathogen-free
conditions in the Animal Care Facility at Beijing Hospital. The
study protocol for the experimental use of the animals was
approved by the Ethics Committee of National Center for Clinical
Laboratories.
Monospecific antibody ELISA and bispecific antibody
ELISA
To test the ability of antibodies to crosslink the same antigens,
carriers or carrier-hapten conjugates in 0.05 M carbonate buffer
(pH 9.6) were coated onto ELISA plates (Costar, USA) at 4uC
overnight. The plates were subsequently washed thoroughly with
phosphate-buffered saline (PBS), and the unbound sites were
blocked with 1% (w/v) gelatin in PBS at 37uC for 2 h. After
washing 3 times with PBS containing 0.05% (w/v) Tween-20
(PBST), 100 mL of serially diluted sera were incubated with
coated antigens at 37uC for 1 h. Blank sera were tested as
controls. Subsequently, the plates were washed as above, and
HRP-labeled carriers or haptens, which were the same as those
used for the coating, were optimally diluted using 0.2% gelatin in
PBST and 100 mL was applied to each well. After incubation at
37uCf o r1h ,1 0 0mL of tetramethyl benzidine (TMB) solution
was added to each well. Color development was terminated after
incubation at 37uC for 30 min by addition of 50 mLo f2M
H2SO4, and the optical density (OD) was measured at 450 nm
(with 620 nm as a reference) using an ELISA plate reader
(Labsystems, Finland).
The procedures for the bispecific antibody ELISA were similar
to those described above, with the exception that the detection
antigens, which were labeled with HRP, were different from the
coating, according to specific situations. Thus, when BSA was the
coated antigen, HRP-labeled digoxin was used to detect the
bispecific antibody against BSA and digoxin. The others were
detected in the same manner. Each serum was detected in
duplicate. The end point dilution titers for each antibody were
defined as the maximum dilution of serum giving an absorbance
reading of 0.1 units over the blank sera wells after subtracting the
background caused by enzyme conjugates.
Bispecific inhibition assay
For inhibition studies, 50 mL of non-labeled digoxin and DNP
at different concentrations in PBS were used as inhibitors and
mixed with an equal volume of HRP-labeled digoxin and HRP-
labeled DNP, respectively. The mixtures were used as a substitute
for 100 mL of HRP-labeled antigens in the bispecific antibody
ELISA.
Size-exclusion chromatography
BSA-digoxin immunized serum (200 mL), which was deter-
mined to contain bispecific antibodies, was subjected to gel
filtration to exclude the involvement of antibody aggregates. Size-
exclusion chromatography was performed on a Bio-Gel A1.5m
(Bio-Rad Laboratories, USA) column (1.5645 cm). The column
was equilibrated and washed with 0.1 M PBS (pH 7.4). Fractions
of 500 mL were collected and analyzed for the bispecificity of the
antibodies. Furthermore, the IgG nature of the antibodies was
determined by a HRP conjugated goat anti-rabbit IgG antibody
(1:20000, Sigma-Aldrich). Briefly, BSA-digoxin conjugates were
coated onto the ELISA plates. After incubation with the sera, the
captured rabbit IgG antibodies to BSA-digoxin were detected by
the anti-rabbit IgG secondary antibody. As a control, human
normal immunoglobulin for intravenous injection (200 mL; Green
Cross China Biological Products, Anhui Province, China), which
comprises primarily IgG monomers, was fractionated on the same
column.
Pepsin digestion
Pepsin digestion of antiserum was carried out as described
previously to exclude IgG Fc-Fc interactions [11–14]. Briefly,
antiserum containing bispecific antibodies against BSA and
digoxin was dialyzed in 0.2 M sodium acetate buffer (pH 4.0)
at 4uC overnight. Protein (2 mg/mL; estimated as 1.546A2802
0.766A260) was mixed with equal volume of 40 mg/mL of pepsin
(Sigma) or acetate buffer. The test samples and controls were
incubated at 37uC. The digestion reaction was stopped by raising
the pH to pH 8.0 using 2 M Tris base at different time intervals.
Products of digestion were analyzed by the bispecific antibody
ELISA.
Purification of bispecific antibodies
Purification of bispecific antibodies against BSA and digoxin
was performed using BSA-Sepharose and digoxin-Sepharose.
Conjugation of BSA to CNBr-activated Sepharose 4B (GE
Healthcare, Amersham Biosciences, Sweden) was conducted
according to the manufacturer’s instructions. The conjugation of
digoxin to v-aminoalkyl Sepharose (GE Healthcare, Amersham
Biosciences, Sweden) was conducted by a previously described
method [15].
First, rabbit immunoglobulins were precipitated by 50%
ammonium sulfate [16]. The precipitates were redissolved in
PBS and fractionated on a protein A (Pharmacia, America)
column according to manufacturer’s protocol. IgG fractions
were collected and pooled, dialyzed against 0.1 M PBS, and
concentrated to about 10 mg/mL. BSA- and digoxin-conjugated
matrixes were equilibrated with 0.1 M PBS (pH 7.4) for
experiments. The immunoglobulin solution was first applied to
the digoxin-Sepharose column. The unbound components,
primarily monospecific antibodies against BSA (anti-BSA), were
collected. The bound antibodies were eluted using 25%
methanol (pH 2.5). The eluted fractions were neutralized
immediately with 10 mM PB (pH 7.4), pooled, and dialyzed.
Then, the eluted portion was loaded to the BSA-Sepharose
column in the same way. The unbound components, which were
monospecific antibodies against digoxin (anti-digoxin), were
collected. The bound antibodies were eluted with 0.2 M
glycine-HCl (pH 2.5). The eluted fractions were neutralized
immediately with 1 M Tris-HCl (pH 9.0) [17], pooled, and
dialyzed. The flow rate for both columns was 1 mL/min. The
antibody activity was evaluated by monospecific antibody
ELISA and bispecific antibody ELISA.
Native Bispecific Antibodies
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Anti-BSA antibodies were obtained from the BSA-immunized
sera using a protein A column. Anti-digoxin antibodies were
purified from the BSA-Sepharose column by the purification
process described above. Female Balb/c nude mice (6–8 weeks)
were purchased from Vital River Laboratory Animal Technology
Co. Ltd (Beijing, China). Mice in the test groups were
administered intravenous injections of the antibody (0.01 mg/
each antibody/mouse), while the mice in the control group were
administered intraperitoneally. Blood samples (75–100 mL) were
drawn at scheduled time points, and centrifuged (10,000g, 5 min).
Sera were collected and stored at 220uC until analysis.
Female New Zealand white rabbits (2.5–4.0 kg) were purchased
from Beijing Xingwang nursery (Beijing, China). Rabbits were
housed in a contained unit of the Animal Facility at Beijing
Hospital (Beijing, China) and kept in cages with food and water.
The administration procedures were almost the same as described
above, except that the dose was 0.4 mg/each antibody/rabbit.
Demonstration of Fab-arm exchange in vitro
A mixture of purified anti-BSA and anti-digoxin, at a final
concentration of 100 mg/mL, was prepared and then reductive
glutathione (GSH) was added to this mixture. The working
concentration of GSH was 0.5 mM [4]. The mixture was incubated
at 37uC for different intervals, and bispecific IgG was identified.
Statistical analyses
The difference between female and male rabbits in bispecific
antibody production was assessed using the paired t-test.
Results
Bispecific antibody could occur naturally in rabbits
Hapten-carrier immunization resulted in production of
bispecific antibody. To investigate the antibody production
patterns by different hapten-carrier conjugates, we allocated 24
New Zealand white rabbits into 6 groups according to the
challenging antigens. Sera were obtained 10 days after the last
injection and the antibody profiles were determined by
monospecific and bispecific antibody ELISAs. Generally, 3 kinds
of antibody were detectable in rabbits immunized with a single
type of conjugate, including BSA-digoxin, BSA-DNP, or KLH-
DNP. These were monospecific antibodies crosslinking haptens or
carriers and bispecific antibodies crosslinking hapten and carrier
(Fig. 1A). The maximum antibody titer was defined as a dilution
giving an absorbance reading of 0.1 units over the blank signals,
Figure 1. Antibody profiles in female rabbits immunized by different antigens. All female rabbits were bled 10 days after the last injection
and sera were collected. Monospecific and bispecific antibody ELISAs were performed to define the antibody profiles. Columns represent the mean
antibody titers of 2 female rabbits in each group. The error bars denote the standard deviation (SD). (A) Monospecific and bispecific antibody profiles
in rabbits immunized with digoxin (n=2), BSA (n=2), BSA-digoxin (n=2), BSA-DNP (n=2), and KLH-DNP (n=2). Rabbits immunized with conjugates
produced a bispecific antibody against carrier and hapten in addition to monospecific antibodies to carriers or haptens. (B) Bispecific antibody
profiles in rabbits immunized with a mixture of BSA-digoxin and KLH-DNP (n=2). As many as 6 different types of bispecific antibodies were
detectable in this group.
doi:10.1371/journal.pone.0010879.g001
Figure 2. Longitude study of antibody production in a BSA-
digoxin immunized rabbit. To monitor antibody production during
immunization, sera were collected with 1-week intervals for 3 months
after the first collection, which was conducted at 4
th week following the
primary immunization. Monospecific and bispecific antibody ELISAs
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conjugates. The log of the sera maximum dilution was plotted
on the Y-axis. In the rabbits immunized with a mixture of BSA-
digoxin and KLH-DNP, as many as 6 different types of bispecific
antibody were detected, including anti-BSA-digoxin, anti-BSA-
DNP, anti-BSA-KLH, anti-KLH-digoxin, anti-KLH-DNP, and
anti-digoxin-DNP antibodies (Fig. 1B). In the control groups,
monospecific anti-BSA could be detected in the BSA group,
whereas no antibody was observed in the digoxin group.
To monitor the production of bispecific antibodies during
immunization, a longitudinal study was conducted in 1 rabbit
immunized with BSA-digoxin. We began to collect the sera at the
4
th week after the primary immunization and with 1-week intervals
for 3 months after that. The results showed that the bispecific
antibody was first detected at the 7
th week. Though the antibody
titers increased along with the immunization period, they were
always lower than monospecific antibodies during the whole
observation period (Fig. 2).
Female rabbits were more prone to produce bispecific
antibodies. To test whether animal gender could influence the
production of bispecific antibodies, 2 female and 2 male rabbits
were included in each group. BSA-digoxin, BSA-DNP and KLH-
DNP groups were involved in the comparison. Sera were collected
consecutively in the last immunization period with 1-week
intervals for 5 weeks. The differences in monospecific and
bispecific antibody titers between the females and males were
evaluated. Generally, antibody responses in female rabbits were
collectively stronger than those in males. In the BSA-digoxin
group, male rabbits did not produce any bispecific antibodies
(Fig. 3A). However, in the BSA-DNP and KLH-DNP groups,
bispecific antibodies were detected in male rabbits, but the titers
were lower than those in females (Fig. 3B, 3C). There was a
significant difference in the titers of the bispecific antibody
between the 6 females and 6 males (P,0.01).
Validation of natural bispecific antibody
Inhibition assays. Inhibition assays were conducted to
validate the specificity of bispecific antibodies. The results
demonstrated that 1 mg/mL of L-lysine DNP resulted in 32
times (titers from 3200 to 100) and 16 times (1600 to 100)
decreased titers in bispecific antibody assays for anti-BSA-DNP
and anti-KLH-DNP respectively, compared with the original test
in which no competitive haptens were added. However, haptens at
10 mg/mL and 100 mg/mL gave comparable results to 1 mg/mL.
For anti-BSA-digoxin bispecific assay, a 4-fold inhibition (12800 to
3200) was achieved by 1 ng/mL of digoxin, an 8-fold (12800 to
1600) by 10 ng/mL, and a 32-fold (12800 to 400) by 100 ng/mL,
compared with those in the original test (Fig. 4).
Bispecific antibodies were composed of IgG
monomers. To exclude the false bispecificity caused by
Figure 3. Comparison of antibody titers in female rabbits to male rabbits. Anti-carrier, anti-hapten, and bispecific antibody titers in the BSA-
digoxin group (A), the BSA-DNP group (B), and the KLH-DNP (C) group were determined by monospecific and bispecific antibody ELISAs, respectively.
Dots represent antibody titers of sera derived from the last 5 consecutive collections of female (n=2, F) or male (n=2, M) rabbits in each group. The
lines denote the means of titers.
doi:10.1371/journal.pone.0010879.g003
Figure 4. Inhibition assays for bispecific antibody. To determine
the specificity of bispecific antibody, unlabeled digoxin (0, 1, 10,
100 ng/mL) or DNP (0, 1, 10, 100 mg/mL) were used as competitors with
the HRP-labeled haptens in bispecific antibody ELISAs and the
decreased antibody titers were plotted.
doi:10.1371/journal.pone.0010879.g004
Native Bispecific Antibodies
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bispecific antibody and a control sample were fractionated on a
Bio-Gel A1.5m column. Two distinct component peaks were
obtained from the bispecific serum. The overlapped results
indicated that the major one (peak 1) corresponded to the
position derived from IgG monomers (Fig. 5A). Moreover, all the
fractions of peaks 1 and 2 were analyzed by bispecific antibody
ELISA and their IgG nature was confirmed using a HRP
conjugated goat anti-rabbit IgG antibody. The results were
expressed as the ELISA end point titers. Anti-BSA-digoxin
bispecific antibodies and total IgG antibodies to BSA-digoxin
were detected in the same fractions corresponding to the peak 1,
whereas the fractions of the peak 2 did not display any antibody
activities (Fig. 5B).
To further validate the bispecific antibodies constituted a certain
fraction of rabbit IgG antibody, we attempted to isolate the anti-
BSA-digoxin bispecific antibodies from the sera. Antibody
reactivity during the purification process was monitored using
Figure 5. Size fractionation of anti-BSA-digoxin bispecific serum. (A) 200 mL of serum containing anti-BSA-digoxin bispecific antibody was
fractionated on a Bio-Gel A1.5m column (a). Two distinct component peaks (peak 1 and peak 2) were obtained from the bispecific serum. A control,
which consisted exclusively of IgG monomers, was separated on the same column with the same chromatographic conditions (b). The elution curves
of bispecific serum and control overlapped after fractionation. (B) All 500 mL fractions of peak 1 and peak 2 were analyzed by bispecific antibody
ELISA and their IgG nature was confirmed using a HRP conjugated goat anti-rabbit IgG antibody. The results were expressed as ELISA end point titers
and plotted against the elution time.
doi:10.1371/journal.pone.0010879.g005
Native Bispecific Antibodies
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obtained from the protein A column contained monospecific
antibodies to digoxin (anti-digoxin), monospecific antibodies to
BSA (anti-BSA), and anti-BSA-digoxin bispecific antibodies. Anti-
BSA antibodies were depleted when passing through the digoxin-
Sepharose column. Thus, the eluted fractions from the column
retained anti-digoxin and anti-BSA-digoxin antibodies. Subse-
quently, BSA-Sepharose was used to remove anti-digoxin
antibodies likewise, and the final collection represented bispecifi-
city only (Fig. 6).
Bispecific antibody was not resulted from Fc-Fc
interaction during detection. The Fc-Fc interaction between
immunoglobulins is a potential source of artifacts in the
measurement of bispecific antibodies [14,18]. In order to
exclude this possibility, we conducted a modified bispecific
antibody ELISA in which the sera were treated with pepsin
before the test. However, the bispecific antibody in our antiserum
was not eliminated after pepsin digestion, although background
binding of monospecific antibodies was observed (Fig. 7).
Bispecific antibody could be generated in vitro and in
vivo
The generation of bispecific antibody by Fab-arm exchange was
demonstrated in vitro and in vivo. After mixing 2 monospecific
antibodies (anti-BSA and anti-digoxin) in vitro under a mild
reductive environment, the bispecific antibodies against BSA and
digoxin were initially observed at the 3
rd hour. It was maintained
with incubation time, but decreased after 72 h (Fig. 8A). For in
vivo test, no bispecific antibody was observed at any time point
after injection in Balb/c nude (immunodeficient) mice (data not
shown). However, in female New Zealand white rabbits, bispecific
antibodies could be detected at the 1
st hour (titer of 10) and the 3
rd
hour (titer of 40) after injection. However, the bispecific antibody
became undetectable at the following time points (Fig. 8B).
Discussion
In this report, we established an animal model for the
production of a natural bispecific antibody by immunization with
synthesized conjugates and conducted a series of studies to
evaluate its characteristics.
Sera from rabbits immunized with BSA-digoxin, BSA-DNP,
and KLH-DNP contained bispecific antibodies against the
corresponding haptens and carriers, whereas such reactivity was
not observed in control sera obtained in parallel. Inhibition assays
confirmed the specificity of bispecific antibodies, because it could
be suppressed to varying degrees by different concentrations of
unlabeled haptens. However, full inhibition was not achieved in
our experiments. Animals immunized with a carrier-hapten
conjugate produce antibodies specific for 3 types of antigenic
determinants: (1) the hapten determinant, (2) unaltered epitopes
on the carrier protein, and (3) new epitopes formed by regions of
both the hapten and carrier molecule in combination [19]. Thus,
unlabeled haptens (unconjugated molecules) could not inhibit the
HRP-labeled haptens (conjugated molecules) binding to bispecific
antibodies when 1 Fab region was against the junction newly
generated during conjugation. Naturally generated bispecific
antibodies were recently described, in which human IgG4 from
allergic patients who received immunotherapy with Betula verrucosa
(Bet v 1) and Fel d 1 (major allergen from cat) manifested
bispecificity [3]. We demonstrated that bispecific antibodies were
also produced naturally in animal models.
There were 6 different types of bispecific antibodies present in
sera of rabbits immunized with BSA-digoxin and KLH-DNP
mixtures. These data suggest that the bispecific antibodies were
readily produced by simultaneous stimulation with 2 distinct
Figure 6. Purification of anti-BSA-digoxin bispecific antibodies.
Anti-BSA-digoxin bispecific antibodies were purified from the serum
using a series of purification methods. IgG fraction was obtained using
50% saturated ammonium sulfate precipitation, followed by passing
through a protein A column. Bispecific antibody was further purified by
affinity chromatography, using digoxin-Sepharose and BSA-Sepharose,
after which a pure antibody fraction possessing bispecificity was
obtained. Monospecific and bispecific antibody ELISAs were performed
to monitor antibody titers during the entire purification process and the
results were plotted.
doi:10.1371/journal.pone.0010879.g006
Figure 7. Pepsin digestion of bispecific serum. Anti-BSA-digoxin
bispecific serum was subjected to pepsin digestion to exclude IgG Fc-Fc
interactions, which could potentially result in false-positive signals in
the bispecific analysis. After incubating the bispecific serum with 40 mg/
mL of pepsin at 37uC for various intervals, the digestion reaction was
stopped at 2, 12, and 24 h. Bispecific antibody was determined in
digested samples and controls. Columns represent the mean optical
densities at 450 nm (OD450) of duplicate measurements. Error bars
denote the standard deviation (SD).
doi:10.1371/journal.pone.0010879.g007
Native Bispecific Antibodies
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was not adequately clarified in the study in relation to Bet v 1 and
Fel d 1 [3].
We also investigated how gender contributed to the production
of bispecific antibodies. In male rabbits (n=6), the titers of
bispecific antibodies were significantly lower than those in females
(n=6, p,0.01). It is generally believed that females generate a
more vigorous immune response than males, but there is no
consensus on the reason(s) underlying this difference [20]. The
most frequent explanations suggest an immunosuppressive effect of
testosterone in males, as demonstrated by immune enhancement
after castration [21–22]. Also, women suffer more frequently and
more severely from dysregulation of the immune system than men
[23–24]. Our results indicated that sex hormones might play a role
in bispecific antibody production. However, larger animal
populations and other researches are necessary to further explore
this.
Longitudinal observations in rabbits revealed that the initial
levels of bispecific antibodies were low, and the titers increased
during immunization periods, along with monospecific antibodies.
The bispecific antibody appeared 2 weeks after the appearance of
antibodies against BSA and at nearly the same time as antibodies
against digoxin. This prompted us to reconsider the origin of the
bispecific antibodies, specifically, whether they were induced by
exchanges between 2 monospecific antibodies (anti-BSA and anti-
digoxin). To examine this, we conducted in vitro and in vivo
experiments as described previously [4]. We demonstrated that
Fab-arm exchanges occurred in vitro in a mild reductive
environment (GSH). However, in vivo, we reproduced this only
in rabbits and failed to demonstrate Fab-arm exchange in mice.
We suggest that a homologous environment may facilitate Fab-
arm exchanges. About 80% of mouse genes have a single
identifiable human orthologue, and fewer than 1% of mouse
genes appear to be truly unique [25]. Thus, the homologous
internal environment may be a requirement for observable human
Fab-arm exchanges in mice. Presumably, the rabbit antibodies
share too little homology with mice.
As determined by size fractionation and rabbit IgG specific
ELISA, the bispecific antibodies were of the IgG isotype and
existed as IgG monomers. Human IgG consists of 4 subclasses (1–
4) that can be recognized by antigen differences in their heavy
chains. Human IgG4 has been reported as a type of native
bispecifc antibody [3–4]. However, in rabbits, only a single IgG
subclass has been identified [26]. An ELISA method was
established to detect rabbit bispecific antibodies by means of
various antigen pairs. Nonetheless, false-positive results caused by
antibody aggregates or Fc-Fc interaction could have been involved
in the detection. However, the bispecific antibody was validated
not only by size chromatography, by comparison with the control,
but also by pepsin digestion. Additionally, we obtained the fraction
of bispecific IgG after serial purification processes.
It has been known for more than half a century that in most
immune sera a population of antibodies exists that is unable to
form precipitates with the antigen [27]. Objectively, bispecific
antibody is another form of non-precipitating antibody. Many
explanations have been proposed for the inability of non-
precipitating antibodies to precipitate with antigens. Steric
interference between 2 Fabs has been mentioned as a possible
mechanism, but the most likely explanation is structure asymme-
try: 1 Fab being different from the other. In principle, this could be
achieved in different ways, such as lack of allelic exclusion, post-
translational modification, and post-secretional modification [28].
In the case of IgG4, Aalberse et al. favored the third explanation.
They hypothesized that IgG4 was secreted by the plasma cells as a
normal symmetry antibody, but subsequently interacts with
another IgG molecule and Fab-arm exchange occurs. This process
results in IgG4 molecules with 2 distinct antigen-binding sites [29].
Likewise, this hypothesis is also applicable to rabbit bispecific
antibodies, because we demonstrated Fab-arm exchanges in vitro
and in vivo. The Fab-arm exchange has been suggested to be a
novel type of modification for generating anti-inflammatory
activity [4]. A comprehensive examination of the significance of
this modification needs further studies.
In summary, we established an animal model for the production
of a natural bispecific antibody and conducted studies to examine
its characteristics. Human bispecific IgG4 and bispecific antibodies
from animal models represent a group of antibody products
resulting from simultaneous stimulation by 2 distinct antigens.
This prompted us to consider similar statuses relevant to human
diseases or therapies. As our results indicated, bispecific antibodies
were produced readily when 2 distinct antigens were used for
simultaneous immunization, and sex hormones may potentially
Figure 8. Demonstration of Fab-arm exchange in vitro and in vivo. (A) Two monospecific antibody preparations (anti-BSA and anti-digoxin)
were mixed in vitro at the presence of 0.5 mM reductive GSH. (B) The mixture of anti-BSA and anti-digoxin was injected in a rabbit. Monospecific and
bispecific antibody ELISAs were performed to monitor antibody titers at different time intervals after mixing anti-BSA with anti-digoxin in vitro or
injecting the mixtures in vivo.
doi:10.1371/journal.pone.0010879.g008
Native Bispecific Antibodies
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modification mechanism challenges the commonly accepted one
antibody–one antigen paradigm and redefines our thinking about
the role and application of naturally produced bispecific
antibodies.
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